Literature DB >> 24002670

Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register.

Maria K Svensson1, Jan Cederholm, Björn Eliasson, Björn Zethelius, Soffia Gudbjörnsdottir.   

Abstract

OBJECTIVE: Reduced renal function and albuminuria predict cardiovascular (CV) events and mortality in type 2 diabetes (T2D). In addition, we evaluated the role of co-existing congestive heart failure (CHF) and other CV risk factors on CV events in a large observational population-based cohort of T2D patients. RESEARCH DESIGN AND METHODS: We included 66,065 patients with T2D who were reported to the National Diabetes Register (NDR) in Sweden between 2003-2006 with a follow-up of 5.7 years. Data on outcomes were collected from the cause of death and hospital discharge registers.
RESULTS: A total of 10% of patients experienced a CV event and 3.7% of these were fatal. Increasing levels of albuminuria and renal impairment were independently associated with increasing risk of CV events and all-cause mortality also when adjusting for CHF. In normoalbuminuric patients, a reduction in renal function is an important predictor of CV events and all-cause mortality. Glycaemic control (high HbA1c), smoking and hyperlipidaemia had important effects on risk for CV events in patients with albuminuria, while high blood pressure, but not glycaemic control, had an effect in patients with normoalbuminuric renal impairment.
CONCLUSION: Albuminuria and renal impairment are independent risk factors for CV outcomes and mortality in T2D, albuminuria being the strongest risk factor and relevant at all levels of renal function. In normoalbuminuric patients, a reduction in renal function is an important predictor of CV events and all-cause mortality.

Entities:  

Keywords:  Type 2 diabetes; albuminuria; cardiovascular disease; congestive heart failure; epidemiology and outcomes; renal function

Mesh:

Year:  2013        PMID: 24002670     DOI: 10.1177/1479164113500798

Source DB:  PubMed          Journal:  Diab Vasc Dis Res        ISSN: 1479-1641            Impact factor:   3.291


  28 in total

1.  Electrical atrial vulnerability and renal complications in type 2 diabetes. Reply to Montaigne D, Coisne A, Sosner P et al [letter].

Authors:  Björn Zethelius; Soffia Gudbjörnsdottir; Björn Eliasson; Katarina Eeg-Olofsson; Ann-Marie Svensson; Jan Cederholm
Journal:  Diabetologia       Date:  2016-02-03       Impact factor: 10.122

2.  Incidence and Associations of Chronic Kidney Disease in Community Participants With Diabetes: A 5-Year Prospective Analysis of the EXTEND45 Study.

Authors:  Louisa Sukkar; Amy Kang; Carinna Hockham; Tamara Young; Min Jun; Celine Foote; Roberto Pecoits-Filho; Brendon Neuen; Kris Rogers; Carol Pollock; Alan Cass; David Sullivan; Germaine Wong; John Knight; David Peiris; Martin Gallagher; Meg Jardine
Journal:  Diabetes Care       Date:  2020-03-11       Impact factor: 19.112

3.  Urinary Lipidomics: evidence for multiple sources and sexual dimorphism in healthy individuals.

Authors:  J Graessler; C S Mehnert; K-M Schulte; S Bergmann; S Strauss; T D Bornstein; J Licinio; M-L Wong; A L Birkenfeld; S R Bornstein
Journal:  Pharmacogenomics J       Date:  2017-06-13       Impact factor: 3.550

4.  Blood pressure level and risk of major cardiovascular events and all-cause of mortality in patients with type 2 diabetes and renal impairment: an observational study from the Swedish National Diabetes Register.

Authors:  Hanri Afghahi; Maria K Svensson; Mirnabi Pirouzifard; Björn Eliasson; Ann-Marie Svensson
Journal:  Diabetologia       Date:  2015-03-14       Impact factor: 10.122

Review 5.  Determinants of mortality in patients with type 2 diabetes: a review.

Authors:  Jana Engelmann; Ulf Manuwald; Constanze Rubach; Joachim Kugler; Andreas L Birkenfeld; Markolf Hanefeld; Ulrike Rothe
Journal:  Rev Endocr Metab Disord       Date:  2016-03       Impact factor: 6.514

6.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

7.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

Review 8.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

Review 9.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  Circulation       Date:  2019-03-17       Impact factor: 29.690

10.  Treatment with insulin analogs and prevalence of cardiovascular complications in patients with type 1 diabetes.

Authors:  Christoph Hasslacher; Justo Lorenzo Bermejo
Journal:  Ther Adv Endocrinol Metab       Date:  2017-10-10       Impact factor: 3.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.